Trial Profile
A Randomized, Open-label Therapeutic Trial Evaluating the Efficacy and Safety of Neridronate (Nerixia) in the Treatment of Osteoporosis in Patients With Thalassemia Major and Severe Thalassemia Intermedia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Neridronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 01 Jul 2012 Results published in the British Journal of Haematology.
- 11 Jun 2010 New trial record